Prostate Cancer
An International Prospective Open-label, Multi-center, Randomized, non-comparative Phase II Study of Lutetium [177Lu] vipivotide tetraxetan (AAA617) alone and Lutetium [177Lu] vipivotide tetraxetan (AAA617) in combination with Androgen Receptor Pathway Inhibitors in patients with PSMA PET scan positive Castration-Resistant Prostate Cancer (CAAA617B12203)
- Details
ClinicalTrials.gov ID:
NCT05849298
Diagnosis Type:
NA
USOR Number:
- Address
,
P: